High SUVmax on FDG-PET indicates pleomorphic subtype in epithelioid malignant pleural mesothelioma: Supportive evidence to reclassify pleomorphic as nonepithelioid histology

Journal of Thoracic Oncology

Volumn 7, Issue 7, 2012, Pages 1192-1197

  Kadota, Kyuichi ^a,b   Kachala, Stefan S ^a   Nitadori, Jun Ichi ^a   Suzuki, Kei ^a   Dunphy, Mark P S ^a   Sima, Camelia S ^a   Travis, William D ^a   Rusch, Valerie W ^a   Adusumilli, Prasad S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

Mesothelioma; Pleomorphic; Pleural neoplasm; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MALE; NECROSIS; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE;

EID: 84862862536     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182519d96     Document Type: Article

References (27)

1. Robinson BW Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-1603. (Pubitemid 41434638)
2. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2007;2:957-965. (Pubitemid 47511601)
3. Curran D, Sahmoud T, Therasse P, van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998;16:145-152. (Pubitemid 28041592)
4. Ak G, Metintas S, Metintas M, et al. Prognostic factors according to the treatment schedule in malignant pleural mesothelioma. J Thorac Oncol 2009;4:1425-1430.
5. Kadota K, Suzuki K, Sima CS, Rusch V W, Adusumilli PS, Travis WD. Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma. J Thorac Oncol 2011;6:896-904.
6. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-3844.
7. Takenaka T, Yano T, Ito K, et al. Biological significance of the maximum standardized uptake values on positron emission tomography in non-small cell lung cancer. J Surg Oncol 2009;100:688-692.
8. Nakamura H, Hirata T, Kitamura H, Nishikawa J. Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers. Ann Thorac Cardiovasc Surg 2009;15:304-310.
9. Nair VS, Barnett PG, Ananth L, Gould MK; Veterans Affairs Solitary Nodule Accuracy Project Cooperative Studies Group. PET scan 18F-fluorodeoxyglucose uptake and prognosis in patients with resected clinical stage IA non-small cell lung cancer. Chest 2010;137:1150-1156.
10. Goodgame B, Pillot GA, Yang Z, et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol 2008;3:130-134. (Pubitemid 351323186)
11. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004;22:3255-3260. (Pubitemid 41103680)
12. Greene F, Page D, Fleming I, et al. AJCC Cancer Staging Manual, 6th ed. New York: Springer, 2002.
13. Craighead JE, Abraham JL, Churg A, et al. The pathology of asbestos-associated diseases of the lungs and pleural cavities: diagnostic criteria and proposed grading schema. Report of the Pneumoconiosis Committee of the College of American Pathologists and the National Institute for Occupational Safety and Health. Arch Pathol Lab Med 1982;106:544-596.
14. Battifora H, McCaughey EWT. Tumours of the Serosal Membranes. Washington, DC: Armed Forces Institute of Pathology, 1995.
15. Travis W, Brambilla E, Muller-Hermelink H, et al. World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus, and Heart. Lyon, France: IARC Press, 2004.
16. van Diest PJ, van der Wall E, Baak J P. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004;57:675-681. (Pubitemid 38901478)
17. Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998;22:934-944. (Pubitemid 28364493)
18. Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer 2010;116:659-669.
19. Baak J P. Mitosis counting in tumors. Hum Pathol 1990;21:683-685. (Pubitemid 20216807)
20. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2006;132:763-768. (Pubitemid 44415880)
21. Gerbaudo VH, Mamede M, Trotman-Dickenson B, Hatabu H, Sugarbaker DJ. FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival. Eur J Nucl Med Mol Imaging 2011;38:810-821.
22. Bénard F, Sterman D, Smith RJ, Kaiser LR, Albelda SM, Alavi A. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 1999;40:1241-1245. (Pubitemid 29385629)
23. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 2005;49 Suppl 1:S27-S32. (Pubitemid 40798841)
24. Visvikis D, Costa DC, Croasdale I, et al. CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET. Eur J Nucl Med Mol Imaging 2003;30:344-353. (Pubitemid 36692858)
25. Komar G, Teräs M, Seppänen M, et al. Comparison of 2D and 3D performance for FDG PET with different acquisition times in oncological patients. Nucl Med Commun 2009;30:16-24.
26. Nowak AK, Francis RJ, Phillips MJ, et al. A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 2010;16:2409-2417.
27. Vesselle H, Salskov A, Turcotte E, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol 2008;3:971-978.